Spiro-thiazolone V1a Receptor Antagonists for Selective Vasopressin Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autistic spectrum disorders, anxiety, depressive disorders, obsessive compulsive disorder, schizophrenia, aggressive behavior, and phase shift sleep disorders, such as jetlag, lack effective biological/pharmaceutical solutions, and existing vasopressin receptor modulators can cause unwanted side effects due to non-selective action on V1a and other receptors.
Innovation Solution
Development of spiro-thiazolone compounds as selective V1a receptor antagonists to treat these conditions, minimizing off-target side effects by specifically targeting the V1a receptor, thereby providing therapeutic benefits without the unwanted effects associated with non-selective vasopressin receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective vasopressin receptor modulators are used, then therapeutic effects on V1a receptor-mediated conditions are achieved, but unwanted side effects occur due to action on other receptors
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (spiro-thiazolone core with particular substituent patterns) that confer selective affinity for the V1a receptor subtype. The molecular structure is optimized to interact specifically with V1a receptor binding sites while avoiding other vasopressin receptor subtypes (V1b, V2) and oxytocin receptors, thereby achieving localized pharmacological action at the desired target.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the spiro-thiazolone compounds, including substituent types (R1-R6 groups), stereochemistry, and structural modifications to the core framework. These parameter optimizations tune the compound's selectivity profile, enhancing V1a receptor affinity while reducing off-target binding to other receptors, thus resolving the contradiction between therapeutic effectiveness and side effect profile.
2Object-affected harmful factors
If selective V1a receptor antagonists are developed, then off-target side effects are minimized, but existing treatments for related disorders remain ineffective
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic approach into two distinct components: (1) a selective V1a receptor antagonist component that addresses conditions mediated by V1a receptors (anxiety, depressive disorders, autistic spectrum disorders, phase shift sleep disorders), and (2) exclusion of activity at other receptor subtypes to avoid their associated side effects. This segmented pharmacological strategy allows treatment of V1a-mediated disorders without interfering with other physiological systems controlled by different vasopressin receptor subtypes or oxytocin receptors.
Solution Approach 2:
The spiro-thiazolone compound acts as an intermediary substance that selectively binds to and blocks V1a receptors without significantly interacting with V1b, V2, or oxytocin receptors. This intermediary role allows the compound to mediate therapeutic effects in V1a-dependent conditions while leaving other receptor-mediated physiological processes undisturbed, thereby maintaining treatment effectiveness while minimizing side effects.
Data Source
AI summary
Spiro-thiazolones of formula Iwherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.